{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:29:48Z","timestamp":1792178988158,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41584-019-0170-5","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T11:05:04Z","timestamp":1548846304000},"page":"180-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Treat-to-target in rheumatoid arthritis \u2014 are we there yet?"],"prefix":"10.1038","volume":"15","author":[{"given":"Ronald","family":"van Vollenhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"170_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0140-6736(14)61468-9","volume":"386","author":"NR Poulter","year":"2015","unstructured":"Poulter, N. R., Prabhakaran, D. & Caulfield, M. Hypertension. Lancet 386, 801\u2013812 (2015).","journal-title":"Lancet"},{"key":"170_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(09)61340-4","volume":"374","author":"P Verdecchia","year":"2009","unstructured":"Verdecchia, P. et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 374, 525\u2013533 (2009).","journal-title":"Lancet"},{"key":"170_CR3","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"DM Nathan","year":"2005","unstructured":"Nathan, D. M. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643\u20132653 (2005).","journal-title":"N. Engl. J. Med."},{"key":"170_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00392-016-1069-7","volume":"106","author":"H Soran","year":"2017","unstructured":"Soran, H., Dent, R. & Durrington, P. Evidence-based goals in LDL-C reduction. Clin. Res. Cardiol. 106, 237\u2013248 (2017).","journal-title":"Clin. Res. Cardiol."},{"key":"170_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631\u2013637 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75, 3\u201315 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.clim.2017.08.009","volume":"186","author":"KL Winthrop","year":"2018","unstructured":"Winthrop, K. L. et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2017. Clin. Immunol. 186, 87\u201393 (2018).","journal-title":"Clin. Immunol."},{"key":"170_CR8","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76, 960\u2013977 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR9","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68, 1\u201326 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"170_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo, M. L. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44\u201348 (1995).","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 39","key":"170_CR11","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha, D. & Smolen, J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin. Exp. Rheumatol. 23 (Suppl. 39), S100\u2013S108 (2005).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Suppl. 85","key":"170_CR12","first-page":"S75","volume":"32","author":"JS Smolen","year":"2014","unstructured":"Smolen, J. S. & Aletaha, D. Scores for all seasons: SDAI and CDAI. Clin. Exp. Rheumatol. 32 (Suppl. 85), S75\u2013S79 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Suppl. 11","key":"170_CR13","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1002\/acr.20621","volume":"63","author":"JK Anderson","year":"2011","unstructured":"Anderson, J. K., Zimmerman, L., Caplan, L. & Michaud, K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res. 63 (Suppl. 11), S14\u2013S36 (2011).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"Suppl. B","key":"170_CR14","doi-asserted-by":"crossref","first-page":"S09","DOI":"10.18553\/jmcp.2011.17.s9-b.S09","volume":"17","author":"K Farheen","year":"2011","unstructured":"Farheen, K. & Agarwal, S. K. Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J. Manag. Care Pharm. 17 (Suppl. B), S09\u2013S13 (2011).","journal-title":"J. Manag. Care Pharm."},{"key":"170_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jbspin.2011.04.008","volume":"79","author":"C Gaujoux-Viala","year":"2012","unstructured":"Gaujoux-Viala, C. et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine 79, 149\u2013155 (2012).","journal-title":"Joint Bone Spine"},{"key":"170_CR16","first-page":"358","volume":"26","author":"MJ Bentley","year":"2008","unstructured":"Bentley, M. J. & Reed, G. W. Simplified composite disease activity measures in rheumatoid arthritis: should they be used in standard care? Clin. Exp. Rheumatol. 26, 358\u2013366 (2008).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Suppl. 43","key":"170_CR17","first-page":"S22","volume":"24","author":"H Makinen","year":"2006","unstructured":"Makinen, H., Hannonen, P. & Sokka, T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin. Exp. Rheumatol. 24 (Suppl. 43), S22\u2013S28 (2006).","journal-title":"Clin. Exp. Rheumatol."},{"key":"170_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13075-017-1346-5","volume":"19","author":"M Schoels","year":"2017","unstructured":"Schoels, M., Alasti, F., Smolen, J. S. & Aletaha, D. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Res. Ther. 19, 155 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"170_CR19","doi-asserted-by":"publisher","unstructured":"Hirsh, J. et al. Limited health literacy predicts patient confusion about patient global assessments of disease activity and rheumatoid arthritis model disease states. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.23692 (2018).","DOI":"10.1002\/acr.23692"},{"key":"170_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fmed.2018.00040","volume":"5","author":"H Canhao","year":"2018","unstructured":"Canhao, H. et al. Common evaluations of disease activity in rheumatoid arthritis reach discordant classifications across different populations. Front. Med. (Lausanne) 5, 40 (2018).","journal-title":"Front. Med. (Lausanne)"},{"key":"170_CR21","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/rheumatology\/kex211","volume":"56","author":"RJO Ferreira","year":"2017","unstructured":"Ferreira, R. J. O. et al. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology 56, 1573\u20131578 (2017).","journal-title":"Rheumatology (Oxford)"},{"key":"170_CR22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","volume":"73","author":"JA Nies van","year":"2014","unstructured":"van Nies, J. A. et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann. Rheum. Dis. 73, 861\u2013870 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR23","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","volume":"353","author":"T Mottonen","year":"1999","unstructured":"Mottonen, T. et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353, 1568\u20131573 (1999).","journal-title":"Lancet"},{"key":"170_CR24","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/art.1780241012","volume":"24","author":"RS Pinals","year":"1981","unstructured":"Pinals, R. S., Masi, A. T. & Larsen, R. A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 24, 1308\u20131315 (1981).","journal-title":"Arthritis Rheum."},{"key":"170_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263\u2013269 (2004).","journal-title":"Lancet"},{"key":"170_CR26","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/ard.2007.071092","volume":"66","author":"SM Verstappen","year":"2007","unstructured":"Verstappen, S. M. et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 66, 1443\u20131449 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","volume":"374","author":"RF Vollenhoven van","year":"2009","unstructured":"van Vollenhoven, R. F. et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (SWEFOT trial): 1-year results of a randomised trial. Lancet 374, 459\u2013466 (2009).","journal-title":"Lancet"},{"key":"170_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","volume":"146","author":"YP Goekoop-Ruiterman","year":"2007","unstructured":"Goekoop-Ruiterman, Y. P. et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 146, 406\u2013415 (2007).","journal-title":"Ann. Intern. Med."},{"key":"170_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1303006","volume":"369","author":"JR O\u2019Dell","year":"2013","unstructured":"O\u2019Dell, J. R. et al. Therapies for active rheumatoid arthritis after methotrexate failure. N. Engl. J. Med. 369, 307\u2013318 (2013).","journal-title":"N. Engl. J. Med."},{"key":"170_CR30","doi-asserted-by":"publisher","first-page":"i4205","DOI":"10.1136\/bmj.i4205","volume":"354","author":"EA Haavardsholm","year":"2016","unstructured":"Haavardsholm, E. A. et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ 354, i4205 (2016).","journal-title":"BMJ"},{"key":"170_CR31","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/annrheumdis-2015-208941","volume":"75","author":"J Dale","year":"2016","unstructured":"Dale, J. et al. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann. Rheum. Dis. 75, 1043\u20131050 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 2","key":"170_CR32","first-page":"A58","volume":"77","author":"S M\u00f8ller-Bisgaard","year":"2018","unstructured":"M\u00f8ller-Bisgaard, S. et al. The value of adding MRI to a clinical treat-to-target strategy in rheumatoid arthritis patients in clinical remission: clinical and radiographic outcomes from the IMAGINE-RA randomised controlled trial [abstract]. Ann. Rheum. Dis. 77 (Suppl. 2), A58 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/ard.2010.146662","volume":"70","author":"MP Wit de","year":"2011","unstructured":"de Wit, M. P., Smolen, J. S., Gossec, L. & van der Heijde, D. M. Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann. Rheum. Dis. 70, 891\u2013895 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492\u2013509 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR35","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.33380","volume":"64","author":"LR Harrold","year":"2012","unstructured":"Harrold, L. R. et al. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum. 64, 630\u2013638 (2012).","journal-title":"Arthritis Rheum."},{"key":"170_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000221","volume":"2","author":"E Gvozdenovic","year":"2016","unstructured":"Gvozdenovic, E. et al. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open 2, e000221 (2016).","journal-title":"RMD Open"},{"key":"170_CR37","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/acr.23343","volume":"70","author":"Z Yu","year":"2018","unstructured":"Yu, Z. et al. Implementation of treat-to-target for rheumatoid arthritis in the US: analysis of baseline data from a randomized controlled trial. Arthritis Care Res. 70, 801\u2013806 (2018).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"170_CR38","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/art.40111","volume":"69","author":"DH Solomon","year":"2017","unstructured":"Solomon, D. H. et al. Implementation of treat-to-target in rheumatoid arthritis through a learning collaborative: results of a randomized controlled trial. Arthritis Rheumatol. 69, 1374\u20131380 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"170_CR39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson, D. T. et al. American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann. Rheum. Dis. 70, 404\u2013413 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/ard.2007.076307","volume":"67","author":"ML Hetland","year":"2008","unstructured":"Hetland, M. L. et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann. Rheum. Dis. 67, 815\u2013822 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR41","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2012-202735","volume":"73","author":"K Horslev-Petersen","year":"2014","unstructured":"Horslev-Petersen, K. et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann. Rheum. Dis. 73, 654\u2013661 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"170_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1891-x","volume":"18","author":"D Glinatsi","year":"2017","unstructured":"Glinatsi, D. et al. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. Trials 18, 161 (2017).","journal-title":"Trials"},{"key":"170_CR43","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor, P. C. et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N. Engl. J. Med. 376, 652\u2013662 (2017).","journal-title":"N. Engl. J. Med."},{"key":"170_CR44","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Vollenhoven van","year":"2012","unstructured":"van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508\u2013519 (2012).","journal-title":"N. Engl. J. Med."},{"key":"170_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann, R. et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390, 457\u2013468 (2017).","journal-title":"Lancet"},{"key":"170_CR46","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/art.40019","volume":"69","author":"K Hambardzumyan","year":"2017","unstructured":"Hambardzumyan, K. et al. A multi-biomarker disease activity score and the choice of second-line therapy in early rheumatoid arthritis after methotrexate failure. Arthritis Rheumatol. 69, 953\u2013963 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"170_CR47","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2013-204339","volume":"73","author":"D Porter","year":"2014","unstructured":"Porter, D., Dale, J. & Sattar, N. How low to aim in rheumatoid arthritis? Learning from other disciplines. Ann. Rheum. Dis. 73, 480\u2013482 (2014).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-019-0170-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-019-0170-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-019-0170-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:18:54Z","timestamp":1684606734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-019-0170-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["170"],"URL":"https:\/\/doi.org\/10.1038\/s41584-019-0170-5","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"30 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.v.V. declares that he has received research support and grants from AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Pfizer and UCB and consultancy fees or honoraria from AbbVie, AstraZeneca, Biogen, Biotest, Bristol Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer and UCB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}